

# Kadason Launches in the U.S.: A Shampoo Formulated Specifically for Seborrheic Dermatitis

*Federally regulated OTC medicated shampoo with 1.80% salicylic acid, manufactured in the United States, is now available direct to consumers*

NEW YORK, NY, UNITED STATES, August 18, 2026 /EINPresswire.com/ -- Ys Pharma Inc. today announced the U.S. launch of [Kadason](#), a medicated shampoo formulated specifically for seborrheic dermatitis. Kadason is available now to U.S. consumers through the brand's direct-to-consumer website at [ys-ph.com](https://ys-ph.com).



Kadason Medicated Shampoo (1.80% salicylic acid), an OTC shampoo formulated for seborrheic dermatitis, now available in the U.S. at [ys-ph.com](https://ys-ph.com)

Seborrheic dermatitis is a chronic, relapsing inflammatory condition of the scalp — distinct from ordinary dandruff, and one that tends to return even after symptoms appear to clear. It affects an estimated 5.86% of the U.S. population, above the global pooled prevalence of 4.38%, according to a systematic review and meta-analysis published in JAMA Dermatology (2024).

“

I tried shampoo after shampoo, and none of them were made for what I actually had.”

*Takayuki Yamamoto, CEO, Ys Pharma Inc.*

Despite how common the condition is, most shampoos on U.S. shelves are marketed for general dandruff rather than for seborrheic dermatitis specifically. Kadason enters the market as a product built expressly for that condition.

A shampoo made for the condition, not just the flakes Kadason is a federally regulated over-the-counter product

containing 1.80% salicylic acid, an active ingredient recognized under the U.S. Food and Drug Administration's OTC Drug Monograph M032 for the control of the symptoms of seborrheic dermatitis. Used regularly, Kadason helps control the flaking, scaling, and itching associated with seborrheic dermatitis of the scalp.

The formulation is oil-free and silicone-free, and includes Tremella fuciformis extract, aloe vera, green tea extract, and dipotassium glycyrrhizate to support scalp hydration and comfort during ongoing use.

Built from personal experience

Kadason was developed in Japan in collaboration with pharmacists, and is manufactured in the United States to U.S. quality and manufacturing standards.

"I had seborrheic dermatitis myself for years — the sleepless nights, the constant itching, the self-consciousness in everyday conversations," said Takayuki Yamamoto, Chief Executive Officer of Ys Pharma Inc. "I tried shampoo after shampoo, and none of them were made for what I actually had. Kadason came out of working closely with pharmacists to build something for people who live with this condition day to day — not just for the occasional flake."

Availability

Kadason is available at [ys-ph.com](https://ys-ph.com) at a suggested retail price of \$34.99. A subscription option is available at \$27.99 per month.

About Ys Pharma Inc.

Ys Pharma Inc. is a U.S.-based company and the official distributor of Kadason Medicated Shampoo, a federally regulated OTC scalp care product for seborrheic dermatitis and dandruff. Originally developed in Japan and now manufactured in the United States, Kadason is designed for consistent, everyday use by people managing a recurring condition. The company is headquartered in New York, NY. Learn more at [ys-ph.com](https://ys-ph.com).

About Seborrheic Dermatitis

Seborrheic dermatitis is a chronic inflammatory skin condition affecting sebum-rich areas of the scalp, face, and upper body. It is characterized by scaling, flaking, redness, and itching, and is typically chronic and relapsing, with a meaningful impact on quality of life.

Product Use Information

Kadason is an over-the-counter drug product. For external use only. Use only as directed. Read and follow the Drug Facts label before use. If irritation occurs or symptoms persist, discontinue use and consult a doctor. Individual results may vary. Consult a dermatologist before use if you have a severe scalp condition.

Yusuke Kamimura  
Ys Pharma Inc.

info@ys-ph.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/934726262>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.